Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years

Clinical Therapeutics

Volumn 31, Issue 1, 2009, Pages 74-88

  Grossman, Loren D ^a   Parlan, Gelasio ^b   Bailey, Allan L ^c   Yee, G ^d   Yu, Maria ^a   Chan, John Y C ^e  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^b Trillium Health Center   (Canada)

^c Spruce Grove   (Canada)

^d LaSalle Medicale   (Canada)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

edema; heart failure; pioglitazone; pulmonary edema

Indexed keywords

ACARBOSE; ANALGESIC AGENT; ANTACID AGENT; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SULFONYLUREA;

ADULT; AGED; AMPUTATION; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MULTICENTER STUDY; NIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHYSICIAN; POST HOC ANALYSIS; PRESCRIPTION; PROSPECTIVE STUDY; QUESTIONNAIRE; RATING SCALE; RECUMBENCY; RISK; SELF EVALUATION; SIDE EFFECT; WEIGHT; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CANADA; DIABETES MELLITUS, TYPE 2; EDEMA; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; WEIGHT GAIN; YOUNG ADULT;

EID: 60349102989     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.01.004     Document Type: Article

References (24)

1. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia. 42 (1999) 1033-1049
2. Desvergne B., and Wahli W. Peroxisome prohferator-activated receptors: Nuclear control of metabolism. Endocr Rev. 20 (1999) 649-688
3. Grossman L.D. New solutions for type 2 diabetes mellitus: The role of pioglitazone. PharmacoEconomics. 20 Suppl 1 (2002) 1-9
4. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 27 (2004) 256-263
5. Lebovitz H.E. Differentiating members of the thiazolidinedione class: A focus on safety. Diabetes Metab Res Rev. 18 Suppl 2 (2002) S23-S29
6. Niemeyer N.V., and Janney L.M. Thiazolidinedione-induced edema. Pharmacotherapy. 22 (2002) 924-929
7. Patel C., Wyne K.L., and McGuire D.K. Thiazolidinediones, peripheral oedema and congestive heart failure: What is the evidence?. Diab Vase Dis Res. 2 (2005) 61-66
8. Mudahar S., Chang A.R., and Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology, and clinical implications. Endocr Pract. 9 (2003) 406-416
9. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ. 166 (2002) 219
10. Macfarlane D.P., and Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure: Implications of emerging data. Am J Cardiovasc Drugs. 6 (2006) 297-304
11. Lago R.M., Singh P.P., and Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given Thiazolidinediones: A meta-analysis ofrandomised trials. Lancet. 370 (2007) 1129-1136
12. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA. 298 (2007) 1180-1188
13. Home P.D., Pocock S.J., Beck-Nielsen H., et al., RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med. 357 (2007) 28-38
14. Belcher G., and Matthews D.R. Safety and tolerabihty of pioglitazone. Exp Clin Endocrinol Diabetes. 108 Suppl 2 (2000) S267-S273
15. Miyazaki Y., Mahankali A., Matsuda M., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 87 (2002) 2784-2791
16. Schrefer S. Mosby's Guide to Physical Examination. 3rd ed. (1995), Mosby-Year Book, St. Louis, Mo
17. World Medical Association (WMA). Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects [WMA Web site]. http://www.wma.net/e/pohcy/b3.htm Accessed May 12, 2008
18. Agresti A. Categorical Data Analysis (1990), John Wiley & Sons, Inc, New York, NY
19. Hanefeld M., Pfutzner A., Forst T., and Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: A 42-month, open-label, observational, primary care study. Curr Med Res Opin. 22 (2006) 1211-1215
20. Jain R., Osei K., Kupfer S., et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 26 (2006) 1388-1395
21. Majima T., Komatsu Y., Doi K., et al. Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J. 53 (2006) 325-330
22. Karter A.J., Ahmed A.T., Liu J., et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 22 (2005) 986-993
23. Srivastava P.M., Calafiore P., Maclsaac R.J., et al. Thiazolidinediones and congestive heart failure-exacerbation or new onset of left ventricular dysfunction?. Diabet Med. 21 (2004) 945-950
24. Tang W.H., Francis G.S., Hoogwerf B.J., and Young J.B. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 41 (2003) 1394-1398